Study Treatment regiment Follow up period (months) Results Ref
TAP *v-PDT 24 V-PDT reduced the risk of moderate or severe vision loss in patients with CNV due to AMD. [3]
VIP *v-PDT 24 In the v-PDT group, VA improvement by at least 5 letters was observed in patients with CNV due to pathologic myopia. [42]
Lam et al. *v-PDT (Asian patients) 24 Median VA improvement was 1.7 lines, but the mean number of PDT retreatments required in the first 2 years was 2.3-lower than in the VIP study. [43]
VISION pegaptanib sodium (0.3 mg) 12 70% of patients lost fewer than 15 letters of visual acuity, as compared with 55% among the controls. Improvement in mean visual acuity was not observed. [115]
ANCHOR ranibizumab (0.3 mg or 0.5 mg) vs.
*v-PDT
12 Ranibizumab was clearly superior to PDT with Respect to both visual acuity (VA) and anatomic (lesion size and CNV leakage) efficacy outcomes. [41]
FOCUS ranibizumab 0.5 mg monthly or sham injections monthly followed by *v-PDT at day zero 24 Combination therapy was more effective than v-PDT alone and had a low rate of adverse events. [116]
PROTECT same-day *v-PDT and ranibizumab 0.5 mg in CNV AMD 12 Improved VA, lesions were stabilized with minimal treatment required after month 3. [117]
MONT BLANC *v-PDT, ranibizumab 0.5 mg
In CNV AMD
12 VA improvements in the combination group are non-inferior to a ranibizumab alone with three ranibizumab doses followed by injections on a monthly regimen. [118]
DENALI *v-PDT+ranibizumab 0.5 mg,
**reduced fluence v-PDT
+ranibizumab 0.5 mg,
ranibizumab 0.5 mg
In CNV AMD
12 DENALI did not demonstrate non-inferior visual acuity gain for v-PDT combination therapy compared with ranibizumab monthly monotherapy. [120]
EVEREST *v-PDT+ranibizumab 0.5 mg in PCV 12 Complete regression of polypoidal lesions in combination therapy group. [119]
RADICAL **v-PDT+within 2 h ranibizumab (0.5mg)+dexamethasone (0.5 mg); vs.
***v-PDT
+ ranibizumab (0.5 mg)
+ dexamethasone (0.5 mg); vs.
ranibizumab only (0.5 mg)
24 Cumulative retreatment rates were lower in all combination groups compared with the ranibizumab monotherapy group. Mean VA change from baseline was not statistically different among the treatment groups. [126]
VALIO *v-PDT
(light applied 30 minutes after the start of verteporfin infusion)
12 Improved VA and angiographic outcomes with an acceptable safety profile compared with standard light application 15 minutes after the start of the infusion [152]
TRIPLE
THERAPY
**v-PDT, 16 h later, dexamethasone (800 μg) and bevacizumab (1.5 mg) 9 Less than 25% of the patients treated with this regimen required additional treatment. [127]
*v-PDT+immediate injection of bevacizumab (1.25 mg)+TA (4 mg)+bevacizumab (1.25 mg) every 3 months 6 Short-term results of this study (at 6 months) showed low rate of retreatments, sustained CNV closure efficacy and visual acuity improvement. [128]
  Same-day **v-PDT
+ dexamethasone (200 μg)
+ bevacizumab (1.5 mg)
13.7 VA was maintained, decreased macular thickness in treatment-naïve or previously treated with anti-VEGF.
The mean number of repeat triple therapy treatments was 0.3 in both mentioned groups.
[129]
CFT: Choroidal foveal thickness; PCV: polyploidal choroidal vasculopathy;
*standard fluence v-PDT: 50 J/cm2, 600 mW/cm2;
**reduced fluence v-PDT: 42 J/cm2, 300 mW/cm2;
***quarter fluence: 15 J/cm2, 180 mW/cm2;
**** low fluence: 25 J/cm2, 300 mW/cm2;
TA: Triamcinolone Acetonide;
VA: Visual Acuity;
v-PDT: verteporfin-photodynamic therapy
Table 1: Summary of clinical trials with v-PDT for choroidal neovascularization.